Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study

Autor: Marisa Orrù, Gian Benedetto Melis, Maurizio Nicola D'Alterio, Anna Maria Paoletti, Angelo Cagnacci, Costantino Di Carlo, Manuela Neri
Přispěvatelé: Paoletti, Anna Maria, Cagnacci, Angelo, DI CARLO, Costantino, Orrù, Marisa Margherita, Neri, Manuela, D'Alterio, Maurizio Nicola, Melis, Gian Benedetto
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
HRT
Placebo-controlled study
menopause
Gastroenterology
Body composition
Endocrinology
insulin resistance
Mineralocorticoid Receptor Antagonists
Estradiol
Progesterone Congeners
Estrogen Replacement Therapy
Obstetrics and Gynecology
Hormone replacement therapy (menopause)
Middle Aged
Menopause
Postmenopause
Treatment Outcome
Adipose Tissue
Homeostatic model assessment
Androstenes
Drug Therapy
Combination
Female
medicine.drug
medicine.medical_specialty
Placebo
Insulin resistance
Body Water
Double-Blind Method
Internal medicine
medicine
Body composition
climacteric symptoms
drospirenone
HRT
insulin resistance
menopause
metabolism
NETA
Humans
climacteric symptoms
drospirenone
metabolism
NETA
business.industry
Body Weight
Drospirenone
Estrogens
medicine.disease
climacteric symptom
Blood pressure
Hot Flashes
Quality of Life
Norethindrone
business
Popis: The study was performed to compare the clinical effect of a hormone replacement therapy (HRT) with two different progestins. Postmenopausal women (PMW) with climacteric symptoms (CS) randomly received for 12 months orally, either placebo (n = 20), 1 mg estradiol (E) plus 0.5 mg noretisterone acetate (NETA; n = 40), or 2 mg drospirenone (DRSP; n = 40), a testosterone- and spironolactone-derived molecule, respectively. Weight (W) declined only during E/DRSP (p
Databáze: OpenAIRE
Externí odkaz: